GLP-1 HEALTH OUTCOMES · HFpEF
GLP-1 Drugs for HFpEF and Obesity
Obesity-related heart failure with preserved ejection fraction has emerged as one of the clearest heart-failure settings for GLP-1-based therapy. The STEP-HFpEF program showed meaningful improvements in symptoms, physical limitations, exercise function and body weight, while later trials expanded the clinical-outcomes picture.
Explore a research discussion about GLP-1 Drugs for HFpEF and Obesity
Contact the research director about evidence analysis, data questions or an associated professional project.
Research brief
Why obesity-related HFpEF became a major GLP-1 evidence area
What HFpEF means
HFpEF stands for heart failure with preserved ejection fraction. A person can have heart-failure symptoms even when the percentage of blood ejected by the left ventricle remains within the preserved range. The problem often involves abnormal filling, increased stiffness, elevated filling pressures, impaired relaxation and multiple systemic contributors.
HFpEF is especially heterogeneous. Some patients have prominent hypertension, atrial fibrillation, CKD or diabetes. Others have a strongly obesity-related phenotype characterized by excess adiposity, inflammation, impaired exercise tolerance and increased circulatory and mechanical burden. This heterogeneity is one reason treatment has historically been challenging.
Why obesity matters in HFpEF
Obesity can contribute to HFpEF through several pathways. Increased blood volume and cardiac workload can raise filling pressures. Adipose tissue can contribute to inflammation and metabolic dysfunction. Sleep-disordered breathing, reduced mobility, insulin resistance and skeletal-muscle changes can also worsen symptoms and exercise limitation.
For this reason, obesity-related HFpEF is not simply heart failure in a person who also happens to have obesity. In many patients, obesity is part of the disease phenotype itself. That created a strong rationale for testing treatments that produce substantial weight loss and may affect multiple metabolic pathways.
STEP-HFpEF at a glance
| Trial feature | STEP-HFpEF |
|---|---|
| Population | Adults with HFpEF and obesity |
| Diabetes status | People with diabetes were not the focus of this trial |
| Intervention | Once-weekly semaglutide 2.4 mg |
| Comparator | Placebo |
| Primary focus | Heart-failure symptoms and physical limitations plus body-weight change |
| Other important measures | Exercise function, inflammatory markers and HF-related outcomes |
| Core interpretation | Semaglutide improved symptoms, physical limitations, exercise function and weight |
The primary publication reported that semaglutide produced larger improvements in symptoms and physical limitations, greater weight loss and improved exercise function compared with placebo. NEJM: Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
STEP-HFpEF DM at a glance
| Trial feature | STEP-HFpEF DM |
|---|---|
| Population | Adults with HFpEF, obesity and type 2 diabetes |
| Intervention | Once-weekly semaglutide 2.4 mg |
| Comparator | Placebo |
| Primary focus | Heart-failure symptoms and physical limitations plus body-weight change |
| Clinical importance | Extended semaglutide evidence into a metabolically higher-risk HFpEF population |
STEP-HFpEF DM showed a similar directional pattern of improvement in symptoms, physical limitations, weight and exercise function in people who also had type 2 diabetes. NEJM: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
STEP-HFpEF vs STEP-HFpEF DM
| Dimension | STEP-HFpEF | STEP-HFpEF DM |
|---|---|---|
| HF phenotype | HFpEF | HFpEF |
| Obesity | Yes | Yes |
| Type 2 diabetes | No diabetes-focused population | Yes |
| Semaglutide dose | 2.4 mg once weekly | 2.4 mg once weekly |
| Main benefit domains | Symptoms, function, exercise capacity, weight | Symptoms, function, exercise capacity, weight |
| Why both matter | Established the obesity-related HFpEF signal | Showed the signal remained relevant with T2D |
Endpoint interpretation guide
KCCQ-CSS
The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score reflects heart-failure symptoms and physical limitations from the patient's perspective.
Six-minute walk distance
A functional test that estimates exercise capacity and can reflect how heart failure affects everyday physical performance.
Body weight
Weight reduction is a major outcome in obesity-related HFpEF, but it should not be treated as identical to heart-failure symptom improvement.
Clinical HF events
Hospitalization or urgent worsening-HF events are harder endpoints and should be interpreted separately from symptom scores.
Separate patient-reported benefit from hard clinical events
The STEP-HFpEF program is especially strong for symptoms, function and weight. Later evidence adds a harder clinical-event layer.
What the STEP-HFpEF trials establish
- Semaglutide 2.4 mg can improve HF-related symptoms and physical limitations in obesity-related HFpEF.
- Exercise function improved in the studied populations.
- Body weight fell substantially relative to placebo.
- The benefit pattern was observed both without and with type 2 diabetes across the two STEP-HFpEF trials.
- These findings support obesity as a meaningful therapeutic target in a major HFpEF phenotype.
What the trials do not establish
- They do not establish the same role for semaglutide in HFrEF.
- They should not be rewritten as proof of reduced all-cause or cardiovascular mortality.
- They do not prove that every GLP-1 drug has the same HFpEF effect.
- They do not show that weight loss is the sole mechanism behind symptom improvement.
- They do not replace standard heart-failure care or management of comorbidities.
Why symptoms and physical limitations matter
HFpEF can produce breathlessness, fatigue, exercise intolerance and major limitations in daily activity. In that context, a therapy that improves validated symptom and function measures can be clinically important even without a mortality endpoint.
The Kansas City Cardiomyopathy Questionnaire is widely used to capture how patients experience heart failure. Changes in KCCQ scores should therefore be taken seriously, but they should also be described accurately as patient-reported health-status outcomes rather than as substitutes for hospitalization or mortality data.
Why exercise function matters
Reduced exercise capacity is one of the defining burdens of HFpEF. Six-minute walk distance provides a practical measure of functional performance. Improvements can reflect changes in symptoms, body weight, hemodynamics, conditioning or a combination of factors.
For obesity-related HFpEF, exercise function is especially meaningful because patients may be limited by both cardiovascular physiology and mechanical or metabolic burden.
How SUMMIT changes the wider HFpEF picture
The tirzepatide SUMMIT trial broadened the evidence base by evaluating a harder composite clinical endpoint involving cardiovascular death or worsening heart-failure events in adults with HFpEF and obesity. It also assessed health status. The trial found a lower risk of the composite endpoint and improved health status with tirzepatide compared with placebo. NEJM: SUMMIT.
This does not make STEP-HFpEF and SUMMIT directly comparable efficacy trials. The studies differ in molecule, design, endpoints and analysis. The most useful interpretation is that the obesity-related HFpEF evidence base now spans both patient-reported and functional outcomes and harder worsening-HF outcomes.
What the 2026 CKM guideline adds
The 2026 cardiovascular-kidney-metabolic guideline gives obesity-related symptomatic HFpEF a clear place within CKM care. In adults with CKM stage 4, obesity and symptomatic HFpEF, it identifies GLP-1-based therapy with proven cardiovascular benefit as indicated to improve CKM risk profile, functional capacity and symptoms and to prevent worsening heart-failure events.
This recommendation reflects the convergence of obesity treatment and cardiovascular care. It does not mean that GLP-1-based therapy replaces HFpEF management more broadly. SGLT2 inhibitors, blood-pressure control, diuretics for congestion, atrial-fibrillation management and treatment of other comorbidities remain important.
Why HFpEF and HFrEF must remain separate
Search queries often use the generic phrase “GLP-1 heart failure.” But the evidence is not generic. HFrEF has a different pathophysiology and a mature guideline-directed treatment framework. The 2026 CKM guideline states that the risk-benefit profile of GLP-1-based therapy in HFrEF remains unclear, especially in the absence of ASCVD.
For this reason, GLP1Scientist treats HFpEF as a distinct evidence cluster rather than using one heart-failure page to imply a universal class effect.
Population Boundary Box
Directly supported
Adults with obesity-related HFpEF, including populations studied in STEP-HFpEF and STEP-HFpEF DM.
Separate but connected evidence
Tirzepatide SUMMIT, which adds harder clinical-event evidence in obesity-related HFpEF.
Not automatically established
Equivalent benefit in HFrEF or in HFpEF without the obesity-related phenotype.
Do not infer
That improvement in KCCQ or six-minute walk distance proves a mortality benefit.
Key HFpEF sources
Continue into drug-specific HFpEF evidence
Compare semaglutide and tirzepatide evidence by trial population and endpoint without treating separate trials as head-to-head evidence.
Turn GLP-1 Drugs for HFpEF and Obesity into an evidence-led discussion
Discuss source interpretation, comparative research, data projects or strategy requirements.
Video explainer
Connected research and evidence context
This video is part of the required connected research layer for the current GLP1Scientist outcomes batch.
Frequently asked questions
Questions about GLP-1 drugs, obesity and HFpEF
What is HFpEF?
HFpEF is heart failure with preserved ejection fraction. Symptoms and impaired function can occur even when the ejection fraction is not reduced.
What did STEP-HFpEF show?
Semaglutide improved heart-failure symptoms and physical limitations, reduced weight and improved exercise function in adults with obesity-related HFpEF.
What is STEP-HFpEF DM?
It extended the semaglutide evidence to adults with obesity-related HFpEF who also had type 2 diabetes.
Does semaglutide reduce mortality in HFpEF?
The STEP-HFpEF program should not be rewritten as proof of mortality reduction. Its strongest findings concern symptoms, physical limitations, exercise function and weight.
Connected ecosystem
Broader research, innovation and professional resources
Explore related technology, business, patent, legal and global research platforms connected with the wider research ecosystem.
Research direction
Research direction by Dr. Rahul Dev
GLP1Scientist treats obesity-related HFpEF as a distinct clinical and evidence phenotype. The research approach separates symptom and functional endpoints from harder clinical events, preserves the difference between semaglutide and tirzepatide trial programs and avoids transferring HFpEF findings to HFrEF.
Future revisions should track additional HFpEF outcome studies, treatment sequencing, direct comparative evidence, longer-term event data and changes in CKM or heart-failure guidance.
Continue your research
Continue through obesity-related heart-failure evidence
GLP-1 HEALTH OUTCOMES
Explore the complete outcomes cluster
Move between the master hub, organ-specific evidence, pivotal trials and the guideline timeline.
GLP1Scientist video overview
This video offers additional platform context. Medical and regulatory claims should be checked against the cited primary sources and current official information.